Silver Book Fact

Cytokines in urine are associated with age-related macular degeneration (AMD) and could be developed as a biomarker and provide a practical tool for early detection

Guymer R, Tao L, Goh J, Liew D, et al. Identification of Urine Biomarkers for AMD. Invest Opthalmol Vis Sci. 2011; 52(7): 4639-4644

Reference

Title
Identification of Urine Biomarkers for AMD
Publication
Invest Opthalmol Vis Sci
Publication Date
2011
Authors
Guymer R, Tao L, Goh J, Liew D, et al.
Volume & Issue
Volume 52, Issue 7
Pages
4639-4644

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • It has been estimated that monthly use of ranibizumab in individuals with age-related macular degeneration (AMD) would reduce the incidence of legal blindness by 72% and visual impairment by 37%,…  
  • The prevalence of age-related macular degeneration (AMD) in the 40 and older population has decreased from an estimated 9.4% from 1988 to 1994, to 6.5% for 2005 to 2008.  
  • Macugen to treat wet age-related macular degeneration (AMD)
    A new FDA-approved ophthalmic drug that treats wet age-related macular degeneration (AMD)– pegaptanib sodium (Macugen)– reduced vision loss in 70% of clinical trial patients.  
  • The NEI-sponsored Ocular Hypertensive Treatment Study (OHTS) found that lowering intraocular pressure (IOP) by at least 20% produced a 50% protective benefit for individuals who had an elevated IOP but…  
  • Screening and treatment for eye disease in all type 2 diabetes patients would result in an estimated net savings of over $472.1 million– in 1994 dollars.